a Listed Company to Offer Newly Issued Shares to Specific Investors “Market Price” means the weighted average price of the Company’s shares listed on the SET for the previous 7 - 15 consecutive
responsibility in the audit within a period of (“the cooling-off period”) · five consecutive years* for audit engagement partner · three consecutive years for EQCR and · two consecutive years for other key audit
consecutive years* for audit engagement partner - three consecutive years for EQR and - two consecutive years for other key audit partner? *For the transitional period (1 January 2019 to 31 December 2023), a
% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
administrative expenses for the three months period ended 31 March 2018 and 2019 at THB 34.11 million and THB 40.14 million respectively. This equals to a surge of 17.68 % in administrative expenses year on year
& expenses (net of tax) from the comparing quarters, the normalized net profit would be approximately THB 72.8 million in 2Q19 comparing to THB 52.4 million in 2Q18 or a surge of 39% . Statement of Financial
. Tambon Tarsit, Amohoe Pluag-daeng, Rayong As of June 30, 2018 the Company and its subsidiary had a significant surge in trade and other receivables when compared to last year which was mainly from an
highest score on the ASEAN CG Scorecard (a gauge administered by the ASEAN Capital Market Forum) in the region for a second consecutive year. The SEC places considerable importance on enabling and